Abstract
Acute myeloid leukemia (AML) is a hematological malignancy characterized by the abnormal proliferation of immature cells of myeloid origin (myeloblasts) in the bone marrow. Although knowledge of the disease has advanced in recent years, AML still has a variable prognosis and a high mortality rate, especially in the elderly. Mutations in TP53 are found in about 8% of de novo AML cases and …